Cardiac resynchronization therapy outcomes in patients under nonoptimal medical therapy

Belén Alvarez-Alvarez MD1  |  Javier García-Seara MD, PhD2  |  Jose L. Martínez-Sande MD, PhD2  |  Moisés Rodríguez-Mañero MD, PhD2  |  Xesús A. Fernández Lópe MD2  |  Laila González-Melchor MD2  |  Rosa M. Agra Bermejo PhD1  |  Diego Iglesias-Alvarez MD1  |  Francisco Gude Sampedro MD, PhD3  |  Carla Díaz-Louzao PhD4  |  José R. González-Juanatey MD, PhD1

2Cardiology Department, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
2Arrhythmia Unit, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
2Epidemiology Department, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
4Unit of Biostatistics, Department of Statistics, Mathematical Analysis, Faculty of Mathematics (USC), Santiago de Compostela, Spain

Correspondence: Belén Alvarez-Alvarez, Cardiology Department, Clinical University Hospital of Santiago de Compostela, Travesía Choupana s/n. 15706, Santiago de Compostela, A Coruña, Spain (belenalvarez85@hotmail.com).

Abstract

Background: Cardiac resynchronization therapy (CRT) is indicated in symptomatic heart failure (HF) patients after achieving optimal medical therapy (OMT). However, many patients may not be under OMT when the CRT device is implanted. Here, we evaluate the long-term benefits of CRT in symptomatic HF patients receiving or not OMT.

Methods: We investigated the effect of OMT on HF developing or death in 328 consecutive patients with a CRT device implanted between 2005 and 2015 in a single tertiary center. After the CRT implant, we categorized the patients into three groups: no OMT, OMT at baseline and after 1 year of follow-up, and OMT only at the 1-year follow-up but not at baseline. We used multivariate Cox proportional hazards model to determine the effect of OMT on clinical outcomes.

Results: One hundred and twenty-two patients (37.2%) received OMT prior to CRT. OMT at baseline was not associated with a reduced risk of death or HF (HR 0.72; 95% CI 0.50-1.02; P = 0.067) compared with no-basal-OMT patients. After CRT, patients without OMT had a higher risk of death or HF than patients who received OMT in follow-up (HR 1.72, 95% CI 1.07-2.78, P = 0.025), and the risk of the patients who received OMT at baseline and at the 1-year follow-up was similar to that of the patients who achieved OMT at the 1-year follow-up (HR 0.90, 95% CI 0.54-1.50, P = 0.682).

Conclusion: Basal OMT prior to CRT is not associated with better outcomes in terms of HF/death compared with no basal OMT. The subgroup of patients who achieved OMT at the 1-year follow-up exhibited a reduced risk of HF and death compared with patients who did not.

Keywords: cardiac resynchronization therapy, death, heart failure, optimal medical therapy
1 | INTRODUCTION

Heart failure (HF) is a highly symptomatic syndrome and remains a common cause of poor quality of life, frequent hospitalization and high mortality. Major clinical trials have demonstrated the benefit of cardiac resynchronization therapy (CRT) with a defibrillator (CRT-D) or pacemaker (CRT-P) in terms of clinical outcomes, HF and/or mortality in patients with mild-to-severe symptomatic HF with prolonged QRS width and left ventricular ejection fraction (LVEF) <35% under OMT. CRT has been shown to reduce mortality, morbidity, and improve quality of life in these patients with a life expectancy exceeding 1 year.1–7

Optimal medical therapy (OMT) consists of 3 neurohormonal antagonist drugs (angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin II receptor blockers [ARBs], beta-blockers [BB], and mineralocorticoid receptor antagonist [MRAs]) that have been shown to improve survival, reduce hospitalizations for HF, and improve symptoms.7–14 Nowadays, ACEIs/ARBs, BBs, and MRAs are cornerstones of HF, and they have class I recommendations in clinical guidelines.7 However, patients may occasionally exhibit side effects or comorbidity conditions with ACEIs/ARBs, BBs, and MRAs; and up-titration of neurohormonal blockers to guideline-recommended doses is not possible.

The addition of CRT should be considered in patients who remain symptomatic despite optimal pharmacological treatment. Our understanding of the benefits of CRT is incomplete, however it has been shown to reduce mortality and HF hospitalizations, symptoms and improve reverse remodeling and quality of life. Up until now, it has been impossible to assess the prognostic impact of CRT in patients without OMT at the time of implant. Here, we evaluate the long-term outcomes of CRT in patients who were not on OMT at the time of implant.

2 | METHODS

This follow-up study included 328 consecutive patients with CRT-D or CRT-P under standard clinical indications in a single tertiary cardiac institution between January 2005 and April 2015. All the patients demonstrated HF symptoms (New York Heart Association [NYHA] functional class II, III, or ambulatory IV symptoms), with ischemic or nonischemic cardiomyopathy, decreased LVEF (≤35%), and prolonged QRS duration (≥120 ms) at the time of implantation. They received pharmacological treatment for HF up-titrated to the maximal tolerated doses according to the European Society of Cardiology guidelines7 for the management of HF at the discretion of the treating cardiologist.

We registered the baseline characteristics of all of the patients: age, gender, NYHA functional class, atrial fibrillation, underlying heart disease, pharmacological therapy, glomerular filtration rate, and hemoglobin. Electrocardiographic parameters included QRS width and morphology. Echocardiographic parameters included LV end-diastolic (LVEDV) and end-systolic volume (LVESV), LVEF, and left atrial diameter (LAD). The patients were followed up in the Heart Failure Clinic every 3 or 6 months and in the CRT-Device Clinic every 6 months. Electrocardiogram and echocardiogram were also performed at the 6-month and 2-year follow-ups and according to the discretion of the HF cardiologist. Treating cardiologists followed a specified protocol to achieve OMT. Patients with decreases in LVESV exceeding 15% and/or improvements in LVEF of more than 5% were considered to be echocardiographic responders. Optimal medical therapy was defined as treatment with ACEIs/ARBs, BBs, and MRAs.

The study satisfied all of the requirements of local ethics committees and complied with the Declaration of Helsinki.

2.1 | Statistical analysis

Continuous variables are expressed as mean ± standard deviation (SD). Categorical data are presented as numbers and percentages. We used the Mann-Whitney and the Kruskal-Wallis tests to compare continuous numerical variables among the groups. The cumulative probability of death and/or HF was calculated using the Kaplan-Meier method. We used the multivariate Cox proportional hazards model to estimate the hazard ratio (HR) and 95% confidence interval (95% CI). We carried out statistical analyses in R using the package “survival,” which is freely available at http://cran.r-project.org.

3 | RESULTS

3.1 | Patient characteristics

The study population included 328 patients (253 men and 75 women; mean age: 70.2 ± 9.5 years) who were consecutively implanted with a CRT device at our institution. The mean follow-up duration was 4.2 ± 2.9 years. Of the 328 patients, 122 (37.2%) were on OMT at baseline. The baseline characteristics are listed in Table 1.

Pharmacotherapy at baseline was as follows: 283 patients (86.3%) were on ACEIs/ARBs, 271 patients (82.6%) were on BBs, and 154 patients (47.0%) were on MRAs. Combinations of drugs prior to CRT were as follows: 112 patients (34.1%) were on ACEIs/ARBs, BBs, and MRAs; 119 patients (36.3%) were on ACEIs/ARBs and BBs; 46 patients (14.0%) were on ACEIs/ARBs or MRAs; and 12 patients (3.7%) were not taking any drugs. Changes in echocardiographic, electrical, and clinical variables during follow-up are listed in Table 1.

We investigated the causes why 206 patients were not under OMT at the time of CRT implant. The most frequent cause was chronic kidney disease with or
TABLE 1 Differences in baseline characteristics and clinical, electrical, and echocardiographic variables of patients on baseline and nonbaseline optimal medical therapy

|                                      | OMT (n = 122) | Non-basal OMT (n = 206) | P-value |
|--------------------------------------|---------------|--------------------------|---------|
| Gender, male, n (%)                  | 96 (78.7)     | 157 (76.2)               | 0.606   |
| Age, y                               | 68.7 ± 9.5    | 71.1 ± 9.4               | 0.030   |
| Ischemic cardiomyopathy, n (%)       | 47 (38.5)     | 72 (35.0)                | 0.515   |
| CRT-D, n (%)                         | 66 (54.1)     | 106 (51.5)               | 0.643   |
| NYHA class, n (%)                    |               |                          |         |
| II                                   | 39 (32.0)     | 40 (19.4)                | 0.030   |
| III                                  | 78 (63.9)     | 152 (73.8)               |         |
| IV                                   | 5 (4.1)       | 14 (6.8)                 |         |
| Diabetes, n (%)                      | 30 (24.6)     | 47 (22.8)                | 0.714   |
| Atrial fibrillation, n (%)           | 43 (35.2)     | 80 (38.8)                | 0.516   |
| AV node ablation, n (%)              | 8 (6.6)       | 17 (8.3)                 | 0.576   |
| Glomerular filtration rate, mL/min × 1.73 m² | 64.2 ± 22.8 | 58.6 ± 24.5             | 0.458   |
| Hemoglobin level, g/dL               | 13.3 ± 1.2    | 13.10 ± 1.8              | 0.241   |
| Coronary sinus vein, n (%)           |               |                          |         |
| Anterior                             | 19 (15.7)     | 50 (24.8)                | 0.021   |
| Lateral                              | 61 (50.4)     | 109 (54.0)               |         |
| Posterior                            | 41 (33.9)     | 43 (21.2)                |         |
| QRS width, ms                        | 164.7 ± 27.1  | 161.2 ± 25.6             | 0.235   |
| LVEDV basal, mL                      | 238.8 ± 76.3  | 161.0 ± 64.8             | 0.008   |
| LVESEV basal, mL                     | 176.7 ± 62.6  | 158.6 ± 58.2             | 0.013   |
| LVEF basal, %                        | 26.4 ± 7.2    | 27.6 ± 7.9               | 0.188   |
| QRS width post, ms                   | 153 ± 26      | 156 ± 29                 | 0.440   |
| LVEF post, %                         | 38.3 ± 12.7   | 38.9 ± 12.9              | 0.614   |
| LVEDV post, mL                       | 182.3 ± 80.1  | 169.8 ± 66.6             | 0.188   |
| LVESEV post, mL                      | 118.1 ± 73.1  | 106.1 ± 54.1             | 0.002   |
| LA post, mm                          | 49.7 ± 9.7    | 48.5 ± 9.7               | 0.367   |
| ∆LVEF, %                             | 11.5 ± 12.7   | 12.1 ± 12.9              | 0.704   |
| ∆LVEF >5%, n (%)                     | 84 (69.4)     | 130 (63.1)               | 0.246   |
| ∆LVESEV, mL                          | 51.6 ± 65.8   | 46.5 ± 58.1              | 0.548   |
| ∆LVESEV >15%, n (%)                  | 72 (80.9)     | 108 (83.7)               | 0.589   |
| ∆QRS, ms                             | 11 ± 31       | 5 ± 36                   | 0.083   |
| Clinical response, n (%)             | 96 (78.7)     | 144 (69.9)               | 0.083   |
| Clinical response, n (%)             |               |                          |         |
| Worse                                | 3 (1.5)       | 1 (0.8)                  | 0.229   |
| No change                            | 59 (28.6)     | 25 (20.5)                |         |
| Improvement 1 class                 | 122 (59.2)    | 76 (62.3)                |         |
| Improvement 2 class                 | 22 (10.7)     | 20 (16.4)                |         |

AV, atrio-ventricular; CRT-D, Defibrillator with Cardiac Resynchronization Therapy; LA, left atrium; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESEV, left ventricular end systolic volume; NYHA, New York Heart Association; OMT, optimal medical therapy; ∆, changes.

Patients without hyperpotasemia in 76 patients (36.6%). The second cause was bradycardia (sinus node dysfunction (39 patients) or high degree atrioventricular block (18 patients) with 57 patients (27.7%). The third cause was symptomatic hypotension (46 patients (22.3%). Other reasons were: the occurrence of ventricular arrhythmias in patients with depressed LVEF in whom an implantable cardioverter defibrillator was indicated (24 patients (11.6%)) and bronchial hyperactivity (3 patients (1.5%)).

3.2 Basal OMT and HF/death

Heart failure or death occurred in 56 out of 122 patients (45.9%) receiving OMT at baseline and in 123 out of 206 patients (59.7%) not receiving OMT at baseline. Patients on OMT showed a significant trend to lower risk of the composite endpoint (P = 0.098). Similar results were obtained when we analyzed HF hospitalizations and death separately (Figure 1).

Multivariable Cox proportional hazards model analyses revealed that basal OMT patients had a similar risk of HF/death during long-term follow-up (HR 0.73, 95% CI 0.50–1.02, P = 0.067) as non-basal-OMT patients. There was also a similar risk for HF (HR 1.40, 95% CI 0.91–2.16, P = 0.126) and death (HR 0.72, 95% CI 0.48–2.16, P = 0.180) in both groups of basal treatment.

3.3 Up-titration of neurohormonal blockers. OMT in follow-up

Up-titration in neurohormonal blockers 1 year after CRT implantation was evaluated. 35 patients died in the first year, and they were excluded. At follow-up, 82 patients (28%) achieved OMT only after CRT, 105 patients (35.8%) had no OMT and 106 patients (36.2%) maintained baseline OMT after CRT. Patients on OMT at the 1-year follow-up were younger, had higher baseline hemoglobin and glomerular filtration rates, and had larger left ventricles. Furthermore, they were in a worse functional class than patients who had received basal OMT, similar to the functional class of the non-OMT group. A poorer glomerular filtration rate was observed in non-OMT patients compared with basal OMT patients and patients with OMT at follow-up. The position of the LV electrode in the coronary sinus was significantly different between the basal and nonbasal OMT groups; the anterior location was more frequent in the nonbasal OMT group, and the posterior location was more frequent in the basal OMT group. However, these differences are not observed after the optimization of pharmacological treatment. Table 2 lists the baseline characteristics and changes according to the treatment in the first year of follow-up.

In the Cox hazards proportion model for death or HF, and death and HF separately, OMT after 1 year of follow-up (HR 0.73, 95% CI 0.50–1.02, P = 0.067) as no-basal-OMT group. A poorer glomerular filtration rate was observed in non-OMT patients compared with basal OMT patients and patients with OMT at follow-up. The position of the LV electrode in the coronary sinus was significantly different between the basal and nonbasal OMT groups; the anterior location was more frequent in the nonbasal-OCT group, and the posterior location was more frequent in the basal OCT group. However, these differences are not observed after the optimization of pharmacological treatment. Table 2 lists the baseline characteristics and changes according to the treatment in the first year of follow-up.
$P = 0.682$). However, the risk of HF hospitalizations in long follow-up was similar for all of the groups (Table 3, Figure 2).

**4 DISCUSSION**

The primary finding of this follow-up study is that patients with no OMT at baseline who had CRT implanted experienced the same clinical outcomes of HF/death compared with patients on OMT at baseline. Furthermore, those patients who achieved OMT at the 1-year follow-up after implantation had a lower risk of HF/death than patients who remained on no-OMT. This study suggests, for the first time, that CRT may promote medical treatment optimization early after implantation and that this optimization is associated with a better outcome.

Combined treatment with OMT and biventricular pacing has been shown to invoke marked reduction in HF/death events, which appear very early and are sustained.$^{7-16}$ This benefit has been observed in patients with mild-to-severe HF symptoms in randomized studies.$^{1-6}$ The European Society of Cardiology Guidelines for clinical practice of HF recommend ACEIs and BBs as an initial step in symptomatic HF, and both of these treatments have been shown to reduce mortality and HF hospitalizations (Class of Recommendation I, Level of Evidence A). In addition, MRAs are recommended when patients remain symptomatic under ACEIs and BBs (Class of Recommendation I, Level of Evidence A). Cardiac resynchronization therapy has been recommended in patients with reduced LVEF and prolonged QRS who remain symptomatic despite optimal pharmacological therapy. However, some patients remain symptomatic and may not be treated with all of the recommended pharmacological treatments for comorbidity conditions or side effects such as hypotension, which inhibits up-titrating to the maximum tolerated evidence-based doses.$^{7-14}$ In the REVERSE study, only 35% of patients were on the target dose of BBs, and 60% were receiving 50% of the target dose.$^6$ Achieving the target doses of neurohormonal treatment has clinical relevance; Schmidt et al.$^{17}$ showed that the use of higher dosages of neurohormonal blockers was associated with reduction of morbidity and mortality after CRT implantation. These authors also demonstrated that super-responders were treated with higher doses of ACEIs/ARBs or BBs. Our results suggest that achieving OMT early after CRT implantation had a prognostic value for reducing death and/or HF hospitalizations; and efforts to achieve OMT necessary. Cardiac resynchronization therapy implantation may help optimize pharmacological treatment during the follow-up period. Such a situation should be recommended as a target in patients with no OMT at the time of implant.

The basal pharmacological treatment in large-scale clinical trials—COMPANION,$^2$ CARE-HF,$^3$ MADIT-CRT,$^4$ and RAFT$^5$—was as follows: 95%, 90%, 77%, and 96%, respectively, with ACEIs/ARBs; 73%, 68%, 93%, and 90%, respectively, with BBs; 54%, 55%, 32% and 42%, respectively, with MRAs. In our series, the percentage of patients on pharmacological treatment prior to CRT was similar (ACEIs or ARBs: 86%, BBs: 83%, MRAs: 47%) to the percentages observed in the large clinical trials. Triple-pharmacological treatment was achieved in 122 patients (37%) at baseline and improved up to 198 patients (60%) 1 year after CRT implantation.

Thus far, scientific attention has largely focused on refining preimplantation patient selection to predict a favorable response to CRT because 30% of patients do not benefit from CRT. Optimization of preimplant HF pharmacological treatment has been considered to be a measure of response of CRT.$^{18}$ However, we have shown that the optimization of pharmacological treatment during the first year of follow-up was associated with a relative risk reduction of HF/
death, which suggests a complementary effect of CRT and up-titration of pharmacological therapy. The reason for this improvement might be that CRT provides acute hemodynamic improvement,\textsuperscript{19 – 22} with an increase in cardiac output and a reduction in pulmonary capillary wedge and improvement in the mechanical activation sequence. Cardiac resynchronization therapy also supports systemic blood pressure and heart rate, enabling an increase in the doses of drugs without the associated risk of lethal bradycardia and

### TABLE 2

Differences in baseline characteristics and clinical, electrical, and echocardiographic variables between patients on basal and 1-year of follow-up optimal medical therapy, optimal medical therapy only at 1-year of follow-up and no-optimal medical therapy

|                                | no-OMT (n = 105) | Basal and 1-year follow-up OMT (n = 106) | OMT at 1-year follow-up (n = 82) | P-value |
|--------------------------------|------------------|----------------------------------------|---------------------------------|---------|
| Gender: male, n (%)            | 84 (80.0)        | 83 (78.3)                               | 59 (72.0)                       | 0.403   |
| Age, y                         | 73.1 ± 7.7       | 67.9 ± 9.8                              | 68.9 ± 9.9                      | 0.000   |
| Ischemic cardiomyopathy, n (%) | 43 (41.0)        | 41 (38.7)                               | 22 (26.8)                       | 0.109   |
| CRT-ICD, n (%)                 | 61 (58.1%)       | 57 (53.8)                               | 39 (47.6)                       | 0.358   |
| NYHA class, n (%)              |                  |                                        |                                 |         |
| II                             | 17 (16.2)        | 39 (36.8)                               | 21 (25.6)                       | 0.006   |
| III                            | 81 (77.1)        | 62 (58.5)                               | 60 (73.2)                       |         |
| IV                             | 7 (6.7)          | 5 (4.7)                                 | 1 (1.2)                         |         |
| Diabetes, n (%)                | 28 (26.7)        | 24 (22.6)                               | 16 (19.5)                       | 0.509   |
| Atrial fibrillation, n (%)     | 40 (38.1)        | 35 (33.0)                               | 31 (37.8)                       | 0.698   |
| AV node ablation, n (%)        | 8 (7.6)          | 7 (6.6)                                 | 7 (8.5)                         | 0.882   |
| Glomerular filtration rate, mL/(min × 1.73 m\(^2\)) | 54.0 ± 21.2 | 66.1 ± 23.1 | 68.7 ± 24.3 | 0.000 |
| Hemoglobin level, g/dL         | 12.8 ± 1.7       | 13.4 ± 1.6                              | 13.7 ± 1.5                      | 0.000   |
| Coronary sinus vein, n (%)     |                  |                                        |                                 |         |
| Anterior                       | 28 (27.2)        | 17 (16.2)                               | 16 (19.8)                       | 0.131   |
| Lateral                        | 49 (47.6)        | 53 (50.5)                               | 48 (59.3)                       |         |
| Posterior                      | 26 (25.2)        | 35 (33.3)                               | 17 (16.6)                       |         |
| QRS width prior, ms            | 162.7 ± 26.8     | 164.5 ± 26.4                            | 162.2 ± 26.4                    | 0.729   |
| LBBB, n (%)                    | 62 (59.0)        | 60 (56.6)                               | 57 (69.5)                       | 0.171   |
| LVEDV basal, mL                | 214.8 ± 63.4     | 241.1 ± 76.7                            | 224.0 ± 72.2                    | 0.051   |
| LVESV basal, mL                | 157.2 ± 54.1     | 179.6 ± 63.4                            | 165.9 ± 63.7                    | 0.042   |
| LVEF basal, %                  | 27.8 ± 7.9       | 26.3 ± 7.2                              | 27.1 ± 7.8                      | 0.097   |
| QRS width post, ms             | 156.9 ± 27.6     | 154.3 ± 26.9                            | 152.4 ± 32.4                    | 0.594   |
| LVEF post, %                   | 39.2 ± 13.3      | 36.9 ± 11.8                             | 37.7 ± 11.8                     | 0.106   |
| LVESV post, mL                 | 174.1 ± 73.3     | 193.0 ± 75.6                            | 193.0 ± 70.3                    | 0.180   |
| LVEF post, mL                  | 106.8 ± 59.1     | 113.7 ± 69.6                            | 108.3 ± 57.2                    | 0.796   |
| ΔLVEF, %                       | 11.0 ± 13.9      | 13.2 ± 13.4                             | 13.4 ± 12.8                     | 0.534   |
| ΔLVEF >5%, n (%)               | 67 (63.8)        | 75 (70.8)                               | 54 (65.9)                       | 0.548   |
| ΔLVESV, mL                     | 44.5 ± 55.7      | 58.3 ± 66.9                             | 52.6 ± 63.2                     | 0.392   |
| ΔLVESV >15%, n (%)             | 50 (82.0)        | 65 (83.3)                               | 54 (85.7)                       | 0.849   |
| ΔQRS, ms                       | 6 ± 34           | 10 ± 29                                 | 8 ± 35                          | 0.558   |
| Clinical response, n (%)       | 76 (72.4)        | 85 (80.2)                               | 61 (74.4)                       | 0.393   |
| Clinical response, n (%)       |                  |                                        |                                 |         |
| Worse                          | 1 (1.0%)         | 0 (0.0)                                 | 1 (1.2)                         | 0.562   |
| No change                      | 28 (26.7)        | 21 (19.8)                               | 20 (24.4)                       |         |
| Improvement 1 class           | 61 (58.1)        | 68 (64.2)                               | 54 (65.9)                       |         |
| Improvement 2 class           | 15 (14.3)        | 17 (16.0)                               | 7 (8.3)                         |         |

AV, atrioventricular; CRT-D, Defibrillator with Cardiac Resynchronization Therapy; LA, left atrium; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left Ventricular end systolic volume; NYHA, New York Heart Association; OMT, Optimal medical therapy; Δ, changes.
TABLE 3 Multivariate Cox proportional hazards model for death, HF hospitalization and death/HF hospitalization in patients regarding to optimal medical therapy at baseline and at 1 y of follow-up

| Variable                        | HR   | 95% CI    | P-value |
|---------------------------------|------|-----------|---------|
| **Death**                       |      |           |         |
| Age                             | 1.07 | 1.04-1.10 | 0.000   |
| Male                            | 1.78 | 0.98-3.21 | 0.058   |
| Ischemic cardiomyopathy         | 1.32 | 0.84-2.10 | 0.231   |
| NYHA class                      |      |           | 0.719   |
| II                              | 1    |           |         |
| III                             | 1.21 | 0.63-2.33 |         |
| IV                              | 1.57 | 0.51-4.82 |         |
| Coronary sinus vein             |      |           | 0.067   |
| Anterior                        | 1    |           |         |
| Lateral                         | 0.73 | 0.45-1.04 | 0.195   |
| Posterior                       | 0.44 | 0.22-0.89 | 0.022   |
| LVEDV                           | 1.02 | 1.05-1.08 | 0.001   |
| LVESV                           | 1.00 | 0.99-1.01 | 0.666   |
| Glomerular filtration rate      | 0.99 | 0.98-1.01 | 0.886   |
| Hemoglobine                     | 0.94 | 0.82-1.08 | 0.387   |
| OMT                             |      |           | 0.000   |
| Basal and 1-year FU OMT        | 1    |           |         |
| No OMT                          | 2.95 | 1.55-5.59 | 0.001   |
| OMT only at 1-year FU          | 1.14 | 0.57-2.27 | 0.719   |
| **HF hospitalization**          |      |           |         |
| Age                             | 1.02 | 0.98-1.05 | 0.230   |
| Male                            | 2.64 | 1.42-4.90 | 0.002   |
| Ischemic cardiomyopathy         | 1.08 | 0.68-1.73 | 0.749   |
| NYHA class                      |      |           | 0.615   |
| II                              | 1    |           |         |
| III                             | 1.30 | 0.72-2.33 | 0.381   |
| IV                              | 1.55 | 0.53-4.54 | 0.426   |
| Coronary sinus vein             |      |           | 0.715   |
| Anterior                        | 1    |           |         |
| Lateral                         | 0.87 | 0.50-1.53 | 0.632   |
| Posterior                       | 0.75 | 0.39-1.48 | 0.413   |
| LVEDV                           | 1.01 | 0.99-1.02 | 0.227   |
| LVESV                           |      |           |         |
| Glomerular filtration rate      | 0.98 | 0.97-0.99 | 0.008   |
| Hemoglobine                     | 1.01 | 0.87-1.17 | 0.910   |
| OMT                             |      |           | 0.125   |
| Basal and 1-year FU OMT        | 1    |           |         |
| No OMT                          | 1.10 | 0.64-1.89 | 0.726   |
| OMT only at 1-year FU          | 0.63 | 0.36-1.13 | 0.125   |
| **HF hospitalizations/Death**   |      |           |         |
| Age                             | 1.04 | 1.02-1.06 | 0.000   |
| Male                            | 1.79 | 1.10-2.94 | 0.022   |
| Ischemic cardiomyopathy         | 1.18 | 0.80-1.75 | 0.399   |

(Continues)
extend further indication of CRT to asymptomatic patients. In addition, a MADIT-CRT substudy assessed the association among pharmacological therapy, outcome, and reverse remodeling. Only ACEI/ARB use was associated with a decreased risk of HF or death, and ACEI/ARB use was directly correlated with LVEF and LVESV. However, this correlation was not demonstrated with BBs, and diuretic use was associated with an increased risk of HF hospitalization or death and an inverse correlation with changes in LVEF and LVESV. Ventricular remodeling and hemodynamic improvement of CRT might explain the reduction of HF/mortality in these patients, regardless of pharmacological therapy. In our study, the optimization of pharmacological treatment with CRT was associated with clinical improvement over the long-term and cardiovascular events compared with no OMT. However, no differences in echocardiographic response have been observed at the 1-year follow-up. The echocardiographic response might be delayed after optimization of pharmacological and mechanical therapies or might require a longer period of therapy before improvements are detectable.

The selection of the optimal candidates for CRT is critical, but the presence of baseline OMT might not be an exclusion criterion. It is clinically important to recognize patients who might tolerate up titration of neurohormonal blockers after CRT implantation because this subgroup of patients exhibits better outcomes.

5 | LIMITATIONS

This investigation was a retrospective study conducted at a single center. As a consequence, the patient sample size was limited. Adjustment of pharmacological treatment was at the discretion of the HF team. However, these aspects are inherent to any real-world analyses. Therefore, our results need to be confirmed in future large, multicenter trials.

6 | CONCLUSION

In this follow-up study, basal OMT prior to CRT implant was not associated with a better outcome. Optimal medical therapy achieved at the 1-year follow-up was associated with a reduced risk of HF/death compared with no-OMT patients. Our results suggest that efforts should be made to achieve medical treatment optimization after CRT implantation to improve outcomes.

CONFLICT OF INTEREST

Authors declare no conflict of interests for this article.

ORCID

Belén Alvarez-Alvarez http://orcid.org/0000-0003-0851-7728
Moisés Rodríguez-Mañero http://orcid.org/0000-0001-7566-9321
Laila González-Melchor http://orcid.org/0000-0002-4065-221X
Francisco Gude Sampedro http://orcid.org/0000-0002-9681-1662

REFERENCES

1. Abraham WT, Fisher WG, Smith AL, et al. Multicenter InSync randomized clinical evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53.
2. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure. N Engl J Med. 2004;350:2140–50.
3. Cleland J, Daubert J, Erdmann E, et al. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
4. Moss AJ, Hall WJ, Cannon DS, et al. Cardiac Resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:1329–38.
5. Tang A, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.
6. Linde C, Abraham WT, Gold MR, et al. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.
7. Schreus R, Wiegerinck RF, Prinzen FW. Exploring the electrophysiological and hemodynamic effects of cardiac resynchronization therapy: from bench to bedside and vice versa. Card Electrophysiol Clin. 2015;7(4):599–608.
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
10. The cardiac insufficiency bisoprolol study II: (CIBIS II): a randomised trial. Lancet. 1999;353:9–13.
11. Packer M, Fowler MB, Rodeck EB, et al. Effect of carvedilol on the mortality of patients with severe chronic heart failure: results of carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.
12. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.
13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.
14. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
15. Goldengerg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370:1694–701.
16. Gold MR, Padhiar A, Mealing S, Sidhu MK, Tsintzos SI, Abraham WT. Long-term extrapolation of clinical benefits among patients with mild heart failure receiving cardiac resynchronization therapy: analysis of the 5-year follow-up from the REVERSE study. JACC Heart Fail. 2015;3(9):691–700.
17. Schmidt S, Hürlimann D, Starck CT, et al. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Eur Heart J. 2014;35(16):1051–60.
18. Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non‐responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017;38:1463–72.
19. How to cite this article: Alvarez-Alvarez B, García-Seara J, Martínez-Sande JL, et al. Cardiac resynchronization therapy outcomes in patients under nonoptimal medical therapy. J Arrhythmia. 2018;34:548–555. https://doi.org/10.1002/joa3.12101.